Fulcrum Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2017 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2017 - 2019
Net Income	-9.73	-97.34	-109.87	-80.85	-70.82	Upgrade
Depreciation & Amortization	1.59	2.17	2.41	2.52	2.38	Upgrade
Loss (Gain) From Sale of Investments	-4.39	-5.99	0.15	0.67	-0.07	Upgrade
Stock-Based Compensation	14.55	14.8	13.35	11.07	7.35	Upgrade
Other Operating Activities	-	-	-0	-	-	Upgrade
Change in Accounts Receivable	-1.56	-0.31	3.41	-1.11	-2.53	Upgrade
Change in Accounts Payable	-1.59	-0.85	-1.18	0.97	1.77	Upgrade
Change in Unearned Revenue	-	-0.93	-3.78	-13.17	7.88	Upgrade
Change in Other Net Operating Assets	-1.1	-2.52	-1.55	1.41	0.38	Upgrade
Operating Cash Flow	-2.22	-90.97	-97.05	-78.48	-53.66	Upgrade
Capital Expenditures	-0.28	-0.51	-1.96	-1.71	-1.34	Upgrade
Investment in Securities	32.51	-36.18	14.38	-127.96	-55.8	Upgrade
Investing Cash Flow	32.23	-36.69	12.41	-129.67	-57.14	Upgrade
Long-Term Debt Repaid	-	-	-	-0.02	-0.05	Upgrade
Net Debt Issued (Repaid)	-	-	-	-0.02	-0.05	Upgrade
Issuance of Common Stock	2.75	118.12	84.32	186.53	71.38	Upgrade
Other Financing Activities	-	-	-	-	-0.19	Upgrade
Financing Cash Flow	2.75	118.12	84.32	186.51	71.13	Upgrade
Net Cash Flow	32.76	-9.54	-0.31	-21.64	-39.66	Upgrade
Free Cash Flow	-2.5	-91.47	-99.01	-80.19	-55	Upgrade
Free Cash Flow Margin	-3.12%	-3261.07%	-1561.23%	-418.47%	-623.34%	Upgrade
Free Cash Flow Per Share	-0.04	-1.49	-2.20	-2.27	-2.17	Upgrade
Cash Interest Paid	-	-	-	-	0	Upgrade
Levered Free Cash Flow	-2.08	-56.72	-58.12	-47.54	-24.98	Upgrade
Unlevered Free Cash Flow	-2.08	-56.72	-58.12	-47.54	-24.98	Upgrade
Change in Net Working Capital	5.55	4.02	1.84	8.75	-11.39	Upgrade

Updated Feb 25, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q